The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression
Open accessAbstract
Recent neuroimaging and postmortem studies have demonstrated abnormalities in glutamatergic transmission in major depression. Glutamate NMDA (N-methyl-d-aspartate) receptors are one of the major mediators of excitatory neurotransmission in the central nervous system. At synaptic sites, NMDA receptors are linked with postsynaptic density protein-95 (PSD-95) that plays a key role in mediating trafficking, clustering, and downstream signaling events, following receptor activation. In this study, we examined the expression of NMDA receptor subunits NR1, NR2A, and NR2B as well as PSD-95 in the anterior prefrontal cortex (PFC) using Western blot method. Cortical samples were obtained from age, gender and postmortem interval matched depressed and psychiatrically healthy controls. The results revealed that there was a reduced expression of the NMDA receptor subunits NR2A (-54%) and NR2B (-48%), and PSD-95 protein level (-40%) in the PFC of depressed subjects relative to controls, with no change in the NR1 subunit. The alterations in NMDA receptor subunits, especially the NR2A and NR2B, as well as PSD-95 suggest an abnormality in the NMDA receptor signaling in the PFC in major depression. Our findings in conjunction with recent clinical, cellular, and neuroimaging studies further implicate the involvement of glutamate neurotransmission in the pathophysiology of depression. This study provides additional evidence that NMDA receptor complex is a target for discovery of novel antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence in support of a reduction of synapse number is provided by reports of decreased levels of synaptic signaling proteins in MDD patients, including decreased levels of glutamate receptor subtypes, presynaptic neurotransmitter vesicle-associated proteins, and postsynaptic structural and functional proteins in the dlPFC, the hippocampus, and other forebrain structures (16–19).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Postmortem studies have demonstrated that patients with depression and related mental illnesses have lower BDNF and/or TRKB mRNA levels (75–77), reduced cortical neuron size (75, 78, 79), lower synaptic protein levels (80), decreased mTOR signaling (81), and fewer dendritic spines/synapses (82, 83) in the PFC.”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [80]
In the citing paper
“Protein expression levels of the NMDA subunits NR2A/NR2B and PSD95 are also reduced in PFC of MDD patients 210”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [210]
In the citing paper
“It is interesting to note that the expression and function of mTORC1 signaling proteins is reduced in postmortem PFC of depressed subjects, which could contribute to decreased synthesis of synaptic proteins in PFC of depressed subjects50,51.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535
Domain Interaction Between NMDA Receptor Subunits and the Postsynaptic Density Protein PSD-95
Kornau, H., Schenker, L. T., Kennedy, M. B., & Seeburg, P. H. (1995) · Science · doi:10.1126/science.7569905 · Cited by 1,916
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Self-citationAnterior prefrontal cortex: insights into function from anatomy and neuroimaging
Ramnani, N., & Owen, A. M. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1343 · Cited by 1,170
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 422
Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders
Gómez de San José, N., Goossens, J., Al Shweiki, M. R., Halbgebauer, S., Oeckl, P., Steinacker, P., Danzer, K. M., Graf, H., Schönfeldt-Lecuona, C., Belbin, O., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.10.010 · Cited by 9
Chen, J., Luo, Y., Liang, X., Kong, X., Xiao, Q., Tang, J., Qi, Y., Tang, Y. C., & Xiu, Y. (2022) · Translational Neuroscience · doi:10.1515/tnsci-2022-0255 · Cited by 9
Millard, S. J., Lum, J. S., Fernandez, F., Weston–Green, K., & Newell, K. A. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110174 · Cited by 11
Guanosine as a promising target for fast-acting antidepressant responses
Camargo, A., & Rodrigues, A. L. S. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173422 · Cited by 9
Dysfunction of GluN3A subunit is involved in depression-like behaviors through synaptic deficits
Zhang, M., Kong, X., Chen, J., Liu, W., Liu, C., Dou, X., Jiang, L. H., Luo, Y., Song, M., Miao, P., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.076 · Cited by 10
Disrupting the α7nAChR–NR2A protein complex exerts antidepressant-like effects
Jiang, A., Su, P., Li, S., Wong, A. H. C., & Liu, F. (2021) · Molecular Brain · doi:10.1186/s13041-021-00817-3 · Cited by 9
Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism
Mucci, F., Arone, A., Gurrieri, R., Weiss, F., Russomanno, G., & Marazziti, D. (2025) · Life · doi:10.3390/life15030391 · Cited by 8
Palhas, M. L. C., Corne, R., & Mongeau, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111533 · Cited by 10
Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments
O’Donnell, P., Etkin, A., & Manji, H. K. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20251212 · Cited by 8
Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence
Parincu, Z., & Iosifescu, D. V. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2192402 · Cited by 9
Ünal, G. Ö., Erkılınç, G., Öztürk, K. H., Doğuç, D. K., & Özmen, Ö. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06445-0 · Cited by 6
Jaber, M. H., Kahwaji, H., Nasr, S., Baz, R., Kim, Y., & Fakhoury, M. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_18 · Cited by 8
Karolewicz, B., Çetin, M., & Arıcıoğlu, F. (2011) · Dspace Repository (Marmara Üniversitesi) · Cited by 8
Self-citationAcero-Castillo, M. C., Correia, M. B. M., Caixeta, F. V., Motta, V., Barros, M., & Maior, R. S. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110088 · Cited by 7
Beanes, G., Caliman‐Fontes, A. T., Souza‐Marques, B., Silva, H. D. S., Leal, G. C.-G., Carneiro, B. A., Guerreiro‐Costa, L. N. F., Figueiredo, A. V., Figueiredo, C. A., Lacerda, A. L. T., et al. (2022) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000517 · Cited by 7
Untargeted Plasma Metabolomic Profiling in Patients with Depressive Disorders: A Preliminary Study
Chernonosov, A. А., Mednova, I. A., Levchuk, L. A., Mazurenko, E. O., Roschina, O. V., Simutkin, G. G., Bokhan, N. A., Koval, V. V., & Ivanova, S. А. (2024) · Metabolites · doi:10.3390/metabo14020110 · Cited by 7
A scientometric analysis of research on the role of NMDA receptor in the treatment of depression
Chen, X., Wang, X., Li, C., Zhang, Y., Feng, S., & Xu, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1394730 · Cited by 7
Narita, S., Onozawa, Y., Yoshihara, E., Nishizawa, D., Numajiri, M., Ikeda, K., & Iwahashi, K. (2018) · East Asian Archives of Psychiatry · doi:10.12809/eaap181712 · Cited by 7
Gao, F., Liu, A., Qi, X., Wang, M., Chen, X., Wei, S., Gao, S., Sun, Y., Sun, P., Li, X., et al. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049374 · Cited by 6
Yu, X., Zhong, K.-L., Chen, C., Fu, J., Chen, F., Zhou, H., Zhang, X., Kim, K., & Pan, J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06464-x · Cited by 7
Lehner, M., Wisłowska-Stanek, A., Gryz, M., Sobolewska, A., Turzyńska, D., Chmielewska, N., Krząścik, P., Skórzewska, A., & Płaźnik, A. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.11.004 · Cited by 7
Min, R., Chen, Z., Wang, Y., Deng, Z., Zhang, Y., & Deng, Y. (2021) · Journal of Proteomics · doi:10.1016/j.jprot.2021.104144 · Cited by 7
Rasheed, M., Wang, H., Wang, C., Sun, J., Chen, Z., & Deng, Y. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15766 · Cited by 7
Dynamic Behavioral and Molecular Changes Induced by Chronic Restraint Stress Exposure in Mice
Prévot, T. D., Chatterjee, D., Knoch, J., Codeluppi-Arrowsmith, S. A., Misquitta, K. A., Fee, C., Newton, D. F., Oh, H., Sibille, E. L., & Banasr, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010167 · Cited by 10
Ping, A., Yang, M., Xu, S., Li, Q., Feng, Y., Gao, K., Wang, S., & Duan, K. (2023) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2023.111210 · Cited by 6
Alterations in Gene Expression in Depression
Donev, R., & Alawam, K. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.07.005 · Cited by 6
Zhang, L., Luo, L., Xue, L., Ran, D., Yang, F. Y., Tang, Q., & Jiang, W. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114299 · Cited by 6
Marques, K. L., Moreira, M. L., Thiele, M. C. M., Cunha-Rodrigues, M. C., & Barradas, P. C. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114571 · Cited by 7
Parthasarathy, A., Hanumanthappa, R., Bulbule, S. R., Kiran, P. C., Nanjaiah, H., Gopinath, G., Siddaiah, B. M., David, M., & Devaraju, K. S. (2024) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.35 · Cited by 6
Bieler, M., Hussain, S., Daaland, E. S. B., Mirrione, M. M., Henn, F. A., & Davanger, S. (2021) · The Journal of Comparative Neurology · doi:10.1002/cne.25155 · Cited by 6
Zhu, Y., Qu, Y., Zhang, J., Hou, J., Fang, J., Shen, J., Xu, C. S., Huang, M., Qiao, H., & An, S.-C. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000660 · Cited by 6
Kweon, J., Vigne, M. M., Fukuda, A. M., Ren, B., Carpenter, L. L., & Brown, J. C. (2024) · Research Square · doi:10.21203/rs.3.rs-4630964/v1 · Cited by 6
Sun, W., Yu, H., Li, X., Wan, Y., Mei, Y., Yang, Y., & An, L. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.117513 · Cited by 5
Loupy, K. M., Dawud, L. M., Zambrano, C. A., Lee, T., Heinze, J. D., Elsayed, A. I., Hassell, J. E., D'Angelo, H. M., Frank, M. G., Maier, S. F., et al. (2025) · NeuroImmunoModulation · doi:10.1159/000544842 · Cited by 5
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury
Plummer, Z., Allen, J., Brand, J., Mayo, L. M., Shultz, S. R., & Christie, B. R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111448 · Cited by 6
Rasheed, M., Tahir, R. A., Maazouzi, M., Wang, H., Li, Y., Chen, Z., & Deng, Y. (2024) · The FASEB Journal · doi:10.1096/fj.202400420rr · Cited by 5
Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder
Liu, R., Liu, N., Ma, L., Liu, Y., Huang, Z., Peng, X., Zhuang, C., Niu, J., Yu, J., & Du, J. (2024) · CNS Drugs · doi:10.1007/s40263-024-01123-x · Cited by 5
Depression proteomic profiling in adolescents with transcriptome analyses in independent cohorts
Sokolov, A. V., Lafta, M. S., Nordberg, D. O. T., Jonsson, J., & Schiöth, H. B. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1372106 · Cited by 7
Talty, C.-E., Murphy, S. F., & VandeVord, P. J. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.09.039 · Cited by 6
Synthesis, Biodistribution, and Radiation Dosimetry of a Novel mGluR5 Radioligand: 18F-AZD9272
Nag, S., Varnäs, K., Arakawa, R., Jahan, M., Schou, M., Farde, L., & Halldin, C. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00680 · Cited by 6
Rajkowska, G. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1056-4_14 · Cited by 5
Deficiency of Kif15 impairing synaptic development leads to mood disorder in mice
He, X., Zhang, W., Chen, X., Dong, Z., Wei, C., Wu, T., Kong, D., Kong, R., Wu, R., Liu, Y., et al. (2025) · PLoS Genetics · doi:10.1371/journal.pgen.1011839 · Cited by 5
Li, R., Huang, X., Lv, S., Liu, Y., Li, R., Li, Q., Zhu, J., Ren, W., Geng, L., Ma, S., et al. (2025) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2025.1662449 · Cited by 4
Uzungil, V., Luza, S., Opazo, C., Mees, I., Li, S., Ang, C., Williamson, N. A., Bush, A. I., Hannan, A. J., & Renoir, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109837 · Cited by 3
Smaga, I., Krzyżanowska, W., Pomierny, B., Maciejska, A., Skórkowska, A., Budziszewska, B., Pilc, A., & Nowak, G. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_176 · Cited by 5
Nitric Oxide Signaling in Depression and Antidepressant Action
Wegener, G., & Joca, S. R. L. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_45 · Cited by 4
Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression
Feyissa, A. M., Woolverton, W. L., Miguel-Hidalgo, J. J., Wang, Z., Kyle, P. B., Hasler, G., Stockmeier, C. A., Iyo, A. H., & Karolewicz, B. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.11.018 · Cited by 126
Self-citationLien, C.-H., Casteele, T. V., Laroy, M., Cauwenberge, M. G. A. V., Peeters, R. R., Sunaert, S. G., Laere, K. V., Dupont, P. J., Bouckaert, F., Emsell, L., et al. (2025) · Cerebral Cortex · doi:10.1093/cercor/bhaf028 · Cited by 4
Neuromodulation and cognition in late-life depression
Mirjalili, M., Blumberger, D. M., Brunoni, A. R., Mulsant, B. H., & Rajji, T. K. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02323-3 · Cited by 3
Srivastava, J., Yadav, J., & Dubey, N. (2026) · Cognitive Neurodynamics · doi:10.1007/s11571-026-10446-y · Cited by 3
Hagihara, H., & Miyakawa, T. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03173-7 · Cited by 3
Yang, T., Xiong, T., Wang, Y., Xi, B., Liu, R., Wang, Z., Zhu, W., Lu, D., Wang, Z., Liu, Z., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01173 · Cited by 3
Biomarkers of Depression: Potential Diagnostic Tools
Perković, M. N., Erjavec, G. N., Štrac, D. Š., & Pivac, N. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_3 · Cited by 3
Dysregulated Protein Synthesis in Major Depressive Disorder
Heaney, C. F., & Raab‐Graham, K. F. (2019) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190686307.013.3 · Cited by 3
Role of Neurotoxicity in Depression
Smaga, I., Krzyżanowska, W., Pomierny, B., Budziszewska, B., Pilc, A., & Nowak, G. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_176 · Cited by 3
Metabotropic Receptors for Glutamate and GABA
Stewart, G. D., Kniazeff, J., Przeau, L., Rondard, P., Pin, J., & Goudet, C. (2012) · InTech eBooks · doi:10.5772/32481 · Cited by 4
Neurodegenerative changes in depression: Excitotoxicity or a deficit of trophic factors?
Kudryashova, I. V. (2015) · Neurochemical Journal · doi:10.1134/s1819712415010043 · Cited by 3
Diagnosis of Major Depressive Disorders: Clinical and Biological Perspectives
Fakhoury, M. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_4 · Cited by 3
Xie, K., Duan, W., Xu, Y., Chen, K., Zheng, X., Zhang, J., Wu, F., & Guo, G. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.05.051 · Cited by 2
Sałaciak, K., Lustyk, K., Jagielska, A., Szafarz, M., Inteiro-Oliveira, S., Diógenes, M. J., Xapelli, S., Schnur, P., Morton, L., Moran, E., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00774 · Cited by 2
Gray matter structural and molecular signatures in Alzheimer's disease and late-life depression
Yang, S., Wang, X., Yan, Y., Zhang, J., Wei, Y., Zhang, D., & Yao, W. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120915 · Cited by 2
Trajectories of late-life depression: insights from molecular imaging
Holmes, S. E., & Smith, G. S. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02340-2 · Cited by 2
The Role of mTOR in Mood Disorders Pathophysiology and Treatment
Réus, G. Z., Pitcher, M. R., Arent, C. O., & Quevedo, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00015-3 · Cited by 2
Tan, T., Jiang, L., He, Z., Ding, X., Xiong, X., Tang, M., Chen, Y., & Tang, Y. (2023) · The Cerebellum · doi:10.1007/s12311-023-01614-5 · Cited by 3
Oh, D. H., Park, S., Park, Y. C., & Kim, S. H. (2011) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2011.00581.x · Cited by 2
GATA1: a novel target for gene therapy in major depressive disorder
Kang, H. J. (2014) · Animal Cells and Systems · doi:10.1080/19768354.2014.968204 · Cited by 2
Luoa, X., Fanga, T. Y., guoa, A. L., Yanga, X., Panga, Y. P., Rena, J., Newellc, K. A., Yubc, Y., Huangbc, X. F., & Liuac, Y. (2018) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000371 · Cited by 2
Distinct Roles of NMDA Receptor GluN2 Subunits in the Effects of Ketamine and Its Enantiomers
Ide, S., & Ikeda, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_10 · Cited by 2
Effect of Androgen Deprivation by Castration on Cognitive Functions and Behaviors: A Review Study
Salimi, Z., Khazaei, M. R., Moradpour, F., Zarei, F., Rashidi, Z., & Ahmadi, S. M. (2021) · Journal of Advances in Medical and Biomedical Research · doi:10.30699/jambs.30.e56871 · Cited by 2
GluN2B on Adult-Born Granule Cells Modulates (R,S)-Ketamine’s Rapid-Acting Effects in Mice
Bulthuis, N. E., McGowan, J. C., Ladner, L. R., LaGamma, C. T., Lim, S. C., Shubeck, C., Brachman, R. A., Sydnor, E., Pavlova, I. P., Seo, D.-O., et al. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae036 · Cited by 3
Pahlajani, S. S., & Najjar, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00004-0 · Cited by 2
Zhu, M. J., Cortese, G. P., & Waites, C. L. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/373597 · Cited by 2
Recourt, K., van Gerven, J., Drenth, N., van der Grond, J., Nishigori, K., van der Wee, N. J., & Jacobs, G. E. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1531375 · Cited by 1
Li, C., Wang, Z., Ye, X., Lv, J., Chen, F., Zhang, Y., Liu, J., Li, X., Duan, J., Wang, Y., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1692751 · Cited by 2
Hünnemeyer, A., Ogama, Y., Crescenzo, F. D., Goeldner, R.-G., Harada, A., Katakabe, T., Scholz, A., Shatillo, Y., Süßmuth, S. D., & Keicher, C. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261481073 · Cited by 1
Depression and the NMDA receptor/NO/cGMP pathway
Araújo, J. R. C., & Monteiro‐Moreira, A. C. D. O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817935-2.00017-9 · Cited by 1
Vitti-Ruela, B. V., Dokkedal‐Silva, V., Piovezan, R. D., Tufik, S., & Andersen, M. L. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114221 · Cited by 1
Abebe, E., Mengstie, M. A., Seid, M. A., & Dejenie, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1051235
Involvement of Glial Cells in the Pathophysiology and Treatment of Depression
Fatimi, H. E., & Khalki, L. (2023) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/978-1-6684-9675-6.ch017 · Cited by 1
Kai, Y.-Z., Xia, C., Shan, Q., & Tang, Z. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1616330 · Cited by 1
The Cortisol/DHEA Ratio and Sexual Function in Women with and without a History of Depression
Dundon, C. M. (2014) · ScholarWorks -A service of University of Vermont Libraries (University of Vermont) · Cited by 1
Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies
Hermes, G., & Sanacora, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_6 · Cited by 1
Dysregulation of the Glutamatergic System in Major Depressive Disorder
Cooper, T. M., & Iosifescu, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-58131-8.00012-4 · Cited by 1
González, C. Á., Zaragozá, C., & Lopez-Munoz, F. J. (2020) · Revista de Investigación y Educación en Ciencias de la Salud (RIECS) · doi:10.37536/riecs.2020.5.2.214 · Cited by 2
Where is the Mechanistic Target of Rapamycin Signaling Pathway in Depression?
Lee, J. A. (2022) · Mood and Emotion · doi:10.35986/me.2022.20.2.23 · Cited by 1
Bulthuis, N. E., McGowan, J. C., Ladner, L. R., LaGamma, C. T., Lim, S. C., Shubeck, C. X., Brachman, R. A., Sydnor, E., Pavlova, I. P., Seo, D.-O., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.28.569043 · Cited by 1
Mediators of synaptic activity in anxiety- and depression-related behaviors
Kiselycznyk, C. (2012) · Figshare
A Role for the Fibroblast Growth Factor Family in Depression and Circadian Rhythms.
Inui, E. G. (2010) · Deep Blue (University of Michigan)
Pereira, V. S. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2011.tde-11082011-132630
Björkholm, C. (2013) · Figshare
Neurotrophin Bdnf and Novel Molecular Targets in Depression
Numakawa, T., Nakajima, S., & Adachi, N. (2013)
Evaluation of the antidepressant potential of dextromethorphan
Nguyen, L. (2015) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6309
Smaga, I., Krzyżanowska, W., Pomierny, B., Maciejska, A., Skórkowska, A., Budziszewska, B., Pilc, A., & Nowak, G. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_176-1
Current awareness in human psychopharmacology
(2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.976
Ghaffari‐Nasab, A., Javani, G., Mohaddes, G., & Alipour, M. R. (2023) · Research Square · doi:10.21203/rs.3.rs-2762123/v1
Kiaee, N. (2023) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2023-15825
Dendritic arbor dynamics and stability in health and disease
Mlostek, M., Zeng, J., Urbańska, M., & Jaworski, J. (2023) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2023-2456
Metadata
- Authors
- Feyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B.
- Affiliations
- University of Mississippi Medical Center (US)
- Corresponding author
- Karolewicz, Beata
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-02
- Volume
- 33
- Issue
- 1
- Pages
- 70-75
- ISSN
- 0278-5846 (ISSN-L)
- PMC
- PMC2655629
- OpenAlex
- W2054535395
- Cited by
- 421
- References
- 46
- Citations by year
- 2026: 19 · 2025: 21 · 2024: 29 · 2023: 28 · 2022: 31 · 2021: 34 · 2020: 34 · 2019: 25 · 2018: 25 · 2017: 14 · 2016: 27 · 2015: 28 · 2014: 24 · 2013: 21 · 2012: 15
- FWCI
- 10.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p20rr017701-10)
- National Institute of Mental Health (R01MH067996, MH67996)
- National Center for Research Resources (P20-RR-017701, RR 17701)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- major depressive disorder, NMDA receptor, NR2A, NR2B, NR1 subunit, PSD-95, prefrontal cortex, glutamatergic neurotransmission, postmortem brain, antidepressant targets, glutamatergic dysfunction
- MeSH terms
- Disks Large Homolog 4 Protein, Adult, Carrier Proteins, Major Depressive Disorder, Female, Humans, Male, Membrane Proteins, Middle Aged, Nerve Tissue Proteins, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Prefrontal Cortex, Intracellular Signaling Peptides and Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review